FranceServier’s $1.55 billion drug failed to slow Becker muscular dystrophy.
Patients with Becker muscular dystrophy still have no approved treatment.
Sevasemten showed promise in a smaller randomized study, but the pivotal Phase 3 trial did not align, Servier said.
Servier is analysing the full dataset, with about $1 billion in potential milestone payments still attached to the deal.
How each outlet framed it
- STAT leans critical
- cites the $1.55B purchase price and the June Edgewise acquisition, framing the failure as a costly reversal of a prior smaller study
Sources: STAT